pharma · Hepatitis B · Mixed Dyslipidemia · ARWR
Arrowhead Pharmaceuticals Ireland
Arrowhead Pharmaceuticals Ireland Limited
Arrowhead Pharmaceuticals is a pharma organization headquartered in Pasadena, USA. It trades on NYSE under ticker ARWR. Primary therapeutic focus areas include Hepatitis B, Mixed Dyslipidemia, Severe Hypertriglyceridemia
177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US HQ
746 Employees
Public company Type
ARWR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US
- Employees
- 746
- Programs
- 63
- Drugs
- 34
- Patents
- 126
ARO-APOC3
Phase 2 · small molecule · Mixed Dyslipidemia
ARO-APOC3 for Mixed Dyslipidemia is a Phase 2 program (small_molecule) at Arrowhead Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).
Internal code AROAPOC3-2003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Arrowhead Pharmaceuticals Ireland Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Mixed Dyslipidemia
- Status
- active
- Trials
- 1